Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYMS | P04818 | 2/20 | 0.72 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.62 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.62 |
| ▸ | LMNA | P02545 | 1/20 | 0.62 |
| ▸ | PARP1 | P09874 | 3/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.59 |
| ▸ | TNKS2 | Q9H2K2 | 2/20 | 0.59 |
| ▸ | NPC1 | O15118 | 1/20 | 0.58 |
| ▸ | USP2 | O75604 | 1/20 | 0.58 |
| ▸ | GLA | P06280 | 1/20 | 0.58 |
| ▸ | GAA | P10253 | 1/20 | 0.58 |
| ▸ | MAPT | P10636 | 1/20 | 0.58 |
| ▸ | HPGD | P15428 | 1/20 | 0.58 |
| ▸ | RAB9A | P51151 | 1/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.58 |
| ▸ | IP6K1 | Q92551 | 1/20 | 0.57 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.57 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.56 |
| ▸ | HTR3A | P46098 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31463101 | 1.00 | TYMS (0.72) | TYMSKDM4EHSD17B10LMNAPARP1 | |
| SCHEMBL6670119 | 0.86 | TYMS (0.63) | TYMSKDM4EHSD17B10LMNAPARP1 | |
| SCHEMBL6651474 | 0.84 | TYMS (1.00) | TYMSPARP1ALDH1A1PIM1PIM2 | |
| SCHEMBL29535139 | 0.82 | KDM4E (0.66) | TYMSKDM4EHSD17B10LMNAPARP1 | |
| SCHEMBL7263029 | 0.82 | KDM4E (0.66) | TYMSKDM4EHSD17B10LMNAPARP1 | |
| SCHEMBL3423481 | 0.82 | KDM4E (0.59) | TYMSKDM4EHSD17B10PARP1TNKS2 | |
| SCHEMBL3115005 | 0.79 | TYMS (0.72) | TYMSKDM4EHSD17B10LMNAPARP1 | |
| SCHEMBL28637729 | 0.79 | KDM4E (0.62) | TYMSKDM4EHSD17B10LMNAPARP1 | |
| SCHEMBL6014177 | 0.79 | TYMS (0.72) | TYMSKDM4EHSD17B10LMNAPARP1 | |
| SCHEMBL29900526 | 0.79 | TYMS (0.72) | TYMSKDM4EHSD17B10LMNAPARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2935246-B1 | ISOQUINOLINONE OR QUINAZOLINONE PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS | GILEAD CALISTOGA LLC (US) | 2018-07-25 | — | — | EP | disclosed |
| US-9951029-B2 | Styryl quinazoline derivatives as pharmaceutically active agents | VICHEM CHEMIE KUTATÓ KFT. (HU) | 2018-04-24 | — | — | US | disclosed |
| EP-3008053-B1 | PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS | GILEAD CALISTOGA LLC (US) | 2018-03-21 | — | — | EP | disclosed |
| US-9411230-B2 | Pattern forming method, electron beam-sensitive or extreme ultraviolet-sensitive composition, resist film, method for manufacturing electronic device using the same, and electronic device | FUJIFILM CORPORATION (JP) | 2016-08-09 | — | — | US | disclosed |
| US-20160194291-A1 | STYRYL QUINAZOLINE DERIVATIVES AS PHARMACEUTICALLY ACTIVE AGENTS | VICHEM CHEMIE KUTATÓ KFT. (HU) | 2016-07-07 | — | — | US | disclosed |
| EP-3030550-A1 | STYRYL QUINAZOLINE DERIVATIVES AS PHARMACEUTICALLY ACTIVE AGENTS | Vichem Chemie Kutató KFT (HU) | 2016-06-15 | — | — | EP | disclosed |
| WO-2015019121-A1 | STYRYL QUINAZOLINE DERIVATIVES AS PHARMACEUTICALLY ACTIVE AGENTS | VICHEM CHEMIE KUTATÓ KFT. (HU) | 2015-02-12 | — | — | WO | disclosed |
| US-20140212796-A1 | PATTERN FORMING METHOD, ELECTRON BEAM-SENSITIVE OR EXTREME ULTRAVIOLET-SENSITIVE COMPOSITION, RESIST FILM, METHOD FOR MANUFACTURING ELECTRONIC DEVICE USING THE SAME, AND ELECTRONIC DEVICE | FUJIFILM CORPORATION (JP) | 2014-07-31 | — | — | US | disclosed |
| US-8183276-B2 | Therapeutic agents | MERCK SHARP & DOHME CORP. | 2012-05-22 | — | — | US | disclosed |
| WO-2007042669-A2 | DERIVATIVES OF 4-AMINO-QUINAZOLINE, PREPARATION METHOD THEREOF AND USE OF SAME IN THERAPEUTICS | SANOFIS-AVENTIS (FR) | 2007-04-19 | — | — | WO | disclosed |
| EP-1230225-A2 | PHARMACEUTICALLY ACTIVE 4-SUBSTITUTED PYRIMIDINE DERIVATIVES | ELI LILLY AND COMPANY (US) | 2002-08-14 | — | — | EP | disclosed |
| WO-2001032632-A2 | PHARMACEUTICALLY ACTIVE 4-SUBSTITUTED PYRIMIDINE DERIVATIVES | ELI LILLY AND COMPANY (US) | 2001-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160194291-A1 | STYRYL QUINAZOLINE DERIVATIVES AS PHARMACEUTICALLY ACTIVE AGENTS | FLT3, BCR, STK3 | TYMS 231/4885KDM4E 4561/4885HSD17B10 2053/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.